AEVIS VICTORIA SA – Swiss Medical Network Extends its CHF 150 Million Syndicated Credit Facility

AEVIS VICTORIA SA

/ Key word(s): Financing

AEVIS VICTORIA SA – Swiss Medical Network Extends its CHF 150 Million Syndicated Credit Facility

03.11.2026 / 07:00 CET/CEST


Press release

Fribourg, 3 November 2026

AEVIS VICTORIA SA – Swiss Medical Network Extends its CHF 150 Million Syndicated Credit Facility

AEVIS VICTORIA SA (AEVIS) announces that its subsidiary Swiss Medical Network SA signed an amendment to extend its CHF 150 million syndicated credit facility with a consortium of nine Swiss banks, led by UBS Switzerland AG as arranger and agent.

The maturity date of the facility, originally set for 25 April 2027, has been extended to 25 April 2028, with an option to extend it for a further year. All other terms and conditions of the facility remain unchanged.

Thanks to improved profitability and a reduction in net debt, Swiss Medical Network has also benefited, since 30 September 2026, from a 100-basis-point reduction in the applicable margin, which is linked to the net debt/EBITDA ratio.

“The early extension of this facility by the entire banking syndicate confirms the banks’ confidence in Swiss Medical Network’s operational and financial trajectory,” says Michel Keusch, CFO of AEVIS.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Marion Schihin, msc@dynamicsgroup.ch, +41 79 705 88 15

About Swiss Medical Network
Swiss Medical Network is one of Switzerland’s two leading private clinic and hospital groups. With a nationwide network of 19 clinics and hospitals, 80 outpatient centres and 22 eye clinics, the group covers a comprehensive range of medical services and offers patients access to high-quality care in 16 cantons. Swiss Medical Network is a pioneer in integrated care. With its VIVA healthcare plan and regional care networks, the group promotes coordinated, patient-centred treatment, setting new standards in Swiss healthcare.  Swiss Medical Network Holding is majority-owned by AEVIS VICTORIA SA, which is listed on the SIX Swiss Exchange. www.swissmedical.net.

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS’s main shareholdings are Swiss Medical Network Holding SA (76.3%, directly and indirectly), the only Swiss private network of hospitals present in the country’s three main language regions, MRH Switzerland AG, a luxury hotel group managing eleven hotels in Switzerland and abroad, Infracore SA (22.6%, directly and indirectly), a listed real estate company (INFRAC.SW) dedicated to healthcare-related infrastructure, Swiss Hotel Properties SA, a hospitality real estate division, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.


End of Media Release


2426830  03.11.2026 CET/CEST

Abivax to Participate in Upcoming Fall Investor Conferences

ABIVAX

/ Key word(s): Conference

Abivax to Participate in Upcoming Fall Investor Conferences

02.11.2026 / 22:05 CET/CEST

The issuer is solely responsible for the content of this announcement.


Abivax to Participate in Upcoming Fall Investor Conferences

PARIS, France – November 2, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced participation in the following upcoming fall investor conferences:

Guggenheim Healthcare Innovation Conference
Boston, Massachusetts
November 9-11, 2026
Fireside Chat: Tuesday, November 10th, 10:30-10:55am ET

LifeSci Capital X Sofinnova Growth & Innovation Summit
London, United Kingdom
November 16, 2026

30th German Equity Forum (Deutsches Eigenkapitalforum)
Frankfurt, Germany
November 23-25, 2026
Corporate Presentation: Monday, November 23rd, 11:40am-12:10pm CET

Evercore ISI 9th Annual Healthcare Conference
Miami, Florida
November 30 – December 2, 2026
Fireside Chat: Wednesday, December 2nd, 7:55-8:15am ET

Piper Sandler 38th Annual Healthcare Conference
New York, New York
December 1-3, 2026
Fireside Chat: Thursday, December 3rd, 8:00-8:25am ET

Webcast links for select presentations will be available in the Investors section of Abivax’s website at www.ir.abivax.com. A replay of the available webcasts will also be available on the Company’s website for a limited time following the conference.

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

Contact:

Abivax SA
Patrick Malloy
SVP, Investor Relations
patrick.malloy@abivax.com
+1 847 987 4878

Media Contact:
LifeSci Communications

Karissa Baltz, PhD
Associate Director
LSC_ABIVAX@lifescicomms.com


02.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


2426792  02.11.2026 CET/CEST

aap Implantate AG: Focus on the trauma business – fully MDR-certified portfolio, new products, expanded sales activities – capital increase to finance the next phase of growth

aap Implantate AG

/ Key word(s): Capital Increase

aap Implantate AG: Focus on the trauma business – fully MDR-certified portfolio, new products, expanded sales activities – capital increase to finance the next phase of growth

02.11.2026 / 15:18 CET/CEST

The issuer is solely responsible for the content of this announcement.


aap Implantate AG: Focus on the trauma business – fully MDR-certified portfolio, new products, expanded sales activities – capital increase to finance the next phase of growth

  • Capital increase with subscription rights for up to 1,486,563 new shares at EUR 1.35 per share
  • Subscription period from November 6 to 20, 2026; oversubscription permitted
  • Full MDR certification of the existing portfolio completed as of March 2026
  • Revenue performance improved significantly over the course of the year; Q3 2026 saw slight year-over-year growth
  • EBITDA continued to improve in the first nine months of 2026
  • US business continues to grow at a double-digit rate on a high comparative basis
  • New products already on the market; additional product launches planned through 2028
  • Sales organization restructured and strengthened internationally
  • New management team, led by COO Cornelius Fink and CFO Nicole Kassel, focuses on sales, efficiency, and cost discipline
  • 2026 forecast confirmed

Berlin, November 2, 2026 – The Management Board of aap Implantate AG (“aap”, ISIN: DE000A3H2101), a manufacturer of “Made in Germany” trauma implants, today resolved — with the approval of the Supervisory Board – to conduct a capital increase against cash contributions with subscription rights from the 2024/I authorized capital (see today’s ad hoc announcement). The share capital is to be increased from EUR 14,716,976.00 by up to EUR 1,486,563.00 to a maximum of EUR 16,203,539.00. The new shares will be offered at a ratio of 9.9:1 at a subscription price of EUR 1.35 and will be entitled to dividends as of January 1, 2026. aap intends to use the proceeds from the offering to strengthen its liquidity base and finance the next phase of growth in the trauma business. In addition, the company plans to convert shareholder loans totaling EUR 1,700,000 into equity. To further strengthen the Company’s equity base, the Management Board also intends, subject to the approval of the Supervisory Board, to increase the Company’s share capital by up to EUR 1,350,000.00 (approximately 9% of the currently existing share capital) against contributions in kind, excluding shareholders’ subscription rights. The contribution in kind is intended to comprise shareholder loans granted to the Company with a nominal amount of EUR 1,700,000.00 (debt-to-equity swap). The implementation of the capital increase against contributions in kind is subject to an audit of the contributions in kind by a court-appointed auditor.

The capital increase against contributions in kind is intended to strengthen the Company’s balance sheet structure by increasing equity while simultaneously eliminating the loan liabilities, thereby reducing the interest expense associated with the shareholder loans.

Restructuring and MDR transformation successfully completed

In recent years, aap has fundamentally restructured its business: US sales operations were transitioned to a lean agent model, and the cost structure was significantly optimized across the Group. The Group’s EBITDA loss decreased from EUR 5.1 million in 2019 to EUR 0.64 million in 2025.

A key milestone in the realignment was the transition to the European Medical Device Regulation (MDR). The complex certification process tied up substantial development resources over several years and resulted in non-capitalizable expenses in the seven-figure euro range. The necessary investments and development expenses have largely been completed. As of March 2026, the entire existing product portfolio has been successfully MDR-certified. This means that aap now has the required MDR certification for its entire existing product portfolio, granting it market access in the EU and other CE-relevant markets.

Profitability in the core business has improved significantly – the turnaround in operating performance continued in Q3

The operating performance of aap continued to improve in the first nine months of 2026. While revenue in the first half of 2026 was still 5% below the prior-year figure, this shortfall was significantly reduced in the third quarter.

The operating recovery continued in the third quarter of 2026. Compared to the previous quarter, revenue rose from EUR 2.8 million to EUR 3.3 million, placing it slightly above the level of the same quarter a year earlier. For the first nine months of 2026, this resulted in a revenue decline of only 2.8% compared to the same period a year earlier. This reflects a gradual improvement in revenue performance over the course of the year.

At the same time, the positive earnings trend continued. EBITDA improved once again in the first nine months of 2026 and exceeded the IFRS profitability threshold. This underscores the progress made in efficiency, cost control, and operational performance.

The US business, which is considered a key growth driver for the Group, continued to show particularly strong momentum. In the third quarter of 2025, aap had already posted an exceptionally strong quarter with an 18% increase in revenue compared to the same quarter of the previous year. Against this high comparative base, performance in the third quarter of 2026 improved even further: Revenue in local currency was a further 2% above the strong prior-year quarter. The fourth quarter also began with the highest monthly order intake of the year.

For the first nine months of 2026, revenue in the US increased by 15% in local currency and by 13% on a euro basis. This positive performance confirms the effectiveness of the realignment of the US business and the growing market acceptance of the products. For the first time since its founding, the US subsidiary posted a positive local earnings result.

Additional momentum was evident in July 2026, with the highest order intake recorded in 2026. Management views this as a positive signal for business development in the coming quarters.

There are three clear growth drivers: products, production, and sales

All three growth drivers have already been set in motion; the proceeds from the offering are intended to accelerate their implementation.

Product innovation – attractive market potential: At the end of the second quarter of 2026, aap launched LOQTEQ® VA Elbow, its first fully MDR-certified new product; LOQTEQ® VA Proximal Humerus has received FDA approval. Additional systems are scheduled to follow gradually through 2028, including VA-Tibia & Fibula, VA Foot & Calcaneus, and the CHBS cannulated head screws. Eleven additional development projects are planned through 2031.

Production processes – increased productivity through automation: aap manufactures all its products in Berlin and mills the implants from solid titanium. Through 2028, the company plans to invest in lathes and milling machines, collaborative robotics, and automated material feeding. The goal is to increase capacity and reduce the number of staff required per implant.

Sales – expansion of international sales: In recent months, aap has restructured its sales organization with clearly defined responsibilities and hired additional sales staff. The company is expanding its presence primarily in Spain, Portugal, Chile, and France. In the first half of 2026, sales in Spain and Portugal already grew by more than 30% each thanks to the new VA products. Management sees further growth potential, particularly in North America, as a result of the sales restructuring.

CEO Rubino Di Girolamo: foundation laid for sustainable growth

Rubino Di Girolamo, Chief Executive Officer (CEO) of aap Implantate AG, explains:

“After years of intensive restructuring efforts, we now see, for the first time, that all the key prerequisites for sustainable growth have been met: a fully MDR-certified portfolio, significantly improved operational profitability, new products on the market, and a strengthened international sales organization. The capital increase is intended to enable us to capitalize on these opportunities more quickly and usher in the next phase of aap’s development.”

New management team focuses on growth and profitability

Since August 2026, Cornelius Fink (COO, responsible for Trauma) and Nicole Kassel (CFO, responsible for finance, procurement, and IT) have joined the Management Board, bringing with them experience in production processes, controlling, and transformation projects. Rubino Di Girolamo will smoothly hand over responsibilities to the new team by December 31, 2026, and will remain associated with aap as a consultant thereafter.

Cornelius Fink, member of the Executive Board (COO) of aap Implantate AG, says:

“The new sales team is on board, the first VA products are already on the market, and concrete plans are in place for investments in new machinery. We now intend to use the proceeds from the offering to drive all three growth levers in a targeted and parallel manner.”

Nicole Kassel, member of the Management Board (CFO) of aap Implantate AG, adds:

“The proceeds from the offering are to be directed specifically toward measures that support growth or improve the cost base. In doing so, we consistently evaluate individual measures based on their contribution to operating performance and earnings.”

A certified portfolio in a growing global market

According to industry estimates, the global market for trauma fixation systems is expected to grow from approximately USD 9.6 billion in 2025 to approximately USD 13.4 billion in 2035. The elbow and the foot and ankle are among the fastest-growing indications – precisely the areas that aap is targeting with its new VA systems.

The business model is geared toward recurring revenue: hospitals and distributors make a one-time investment in surgical sets; plates and screws are reordered for each specific surgery. aap holds product registrations in 46 countries and aims for average double-digit annual revenue growth starting in 2027.

Outlook: 2026 forecast confirmed; growth contributions expected starting in 2027

Despite significant losses in the Middle East, the Management Board confirms its forecast for 2026, with revenue of EUR 11.5 million to EUR 14.5 million and EBITDA of EUR -1.0 million to EUR +1.5 million. Regarding EBITDA, the Management Board continues to expect a positive result in the middle of the forecast range. The new products will be introduced gradually and are expected to make a significant contribution to earnings growth starting in 2027.

Rubino Di Girolamo adds:

“With this capital increase, we aim to create the conditions – on a significantly improved operational footing – to finance our next steps toward growth. At the same time, we are enabling our shareholders to maintain their ownership stake through their subscription rights and to participate in the company’s continued development.”

Key details of the subscription offering

The subscription period (indirect subscription rights) is expected to run from November 6 to November 20, 2026. Subscription rights will not be traded; unexercised subscription rights will expire. All shareholders may subscribe for additional shares beyond their subscription rights. Such oversubscription must also be exercised within the subscription period. Shares not subscribed for as part of the capital increase are to be offered to selected investors in a private placement at no less than the subscription price. The subscription offer is expected to be announced in the Federal Gazette on November 4, 2026. The lead underwriter is BankM AG.

About aap Implantate AG

Based in Berlin, aap Implantate AG develops, manufactures, and distributes implants for trauma surgery. At the core of its product portfolio is the patented LOQTEQ® plate system, which combines fracture compression and angle-stable fixation in a single surgical step. All existing products are MDR-certified and are 100% manufactured in Berlin. In Germany, aap sells directly to hospitals and purchasing groups; internationally, it sells through distributors; and in the U.S., it sells through its subsidiary, aap Implants Inc. Product registrations are in place in 46 countries. In addition, aap has a patented antibacterial silver-coating technology that has already passed clinical trials and is seeking approval. The stock is listed on the regulated market of the Frankfurt Stock Exchange (General Standard) (ISIN: DE000A3H2101, WKN: A3H210).

www.aap.de
 

Contact Investor Relations:

CROSS ALLIANCE communication GmbH
Susan Hoffmeister
Phone: +49 89 125 09 0333
Email: sh@crossalliance.de
www.crossalliance.de

Important notice

This announcement is for informational purposes only and does not constitute an offer to sell or a solicitation of an offer to buy or subscribe for securities of aap Implantate AG. The offering is governed exclusively by the subscription offer published in the Federal Gazette. This announcement is not intended for publication or distribution in or within the United States of America, Canada, Australia, or Japan. It may contain forward-looking statements based on the current expectations of the Management Board and subject to risks and uncertainties; actual results may differ materially.

 

 


02.11.2026 CET/CEST Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 019-0
Fax: +49 (0) 30 75 019-111
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 39120001TRQTQ01LPP57
EQS News ID: 2426666

 
End of News EQS News Service

2426666  02.11.2026 CET/CEST

aap Implantate AG: Rights issue from authorized capital and intended capital increase against contributions in kind

aap Implantate AG / Key word(s): Capital measures / Capital increase

aap Implantate AG: Rights issue from authorized capital and intended capital increase against contributions in kind

02-Nov-2026 / 15:10 CET/CEST

Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by EQS News – a service of EQS Group.

The issuer is solely responsible for the content of this announcement.


aap Implantate AG: Rights issue from authorized capital and intended capital increase against contributions in kind

Berlin, November 2, 2026 – The Management Board of aap Implantate AG (“aap” or the “Company”) today resolved, with the approval of the Supervisory Board, to carry out a capital increase against cash contributions with subscription and oversubscription rights for the Company’s shareholders from Authorized Capital 2024/I. In this context, the share capital of aap is to be increased from currently EUR 14,716,976.00 by up to EUR 1,486,563.00 through the issuance of up to 1,486,563 new no-par value bearer shares to up to EUR 16,203,539.00. The new shares are to be offered to the Company’s shareholders at a subscription ratio of 9.9 to 1 and at a subscription price of EUR 1.35 per new share. The new shares will carry dividend rights from 1 January 2026. Subscription rights for fractional amounts will be excluded.

The proceeds from the transaction are intended to be used to strengthen the liquidity position of aap.

The new shares will be offered to the shareholders of aap for subscription by way of an indirect subscription right during a subscription period. The subscription period is expected to commence on 6 November 2026 at 0:00 CET and to end on 20 November 2026 at 24:00 CET. No trading in subscription rights will be arranged, and any subscription rights not exercised will expire without value. In addition, all shareholders of the Company will have the option to participate in the capital increase beyond the exercise of their subscription rights by way of oversubscription. These oversubscription rights must also be exercised within the subscription period. New shares not subscribed for as part of the rights offering are to be offered to investors by way of a private placement at a price at least equal to the subscription price per new share.

In order to further strengthen the Company’s equity base, the Management Board also intends, with the approval of the Supervisory Board and by making further partial use of Authorized Capital 2024/I or Authorized Capital 2026/I, to increase the Company’s share capital by up to EUR 1,350,000.00 (approximately 9% of the currently existing share capital) against contributions in kind and excluding shareholders’ subscription rights. The contribution in kind is intended to comprise shareholder loans granted to the Company with a nominal amount of EUR 1,700,000.00, which are to be contributed to the Company by way of a debt-to-equity swap in exchange for the issuance of up to a further 1,350,000 new shares. The implementation of the capital increase against contributions in kind requires an audit of the contribution in kind by a court-appointed auditor.

The capital increase against contributions in kind is intended to strengthen the balance sheet structure of aap by increasing equity while simultaneously eliminating the loan liabilities and will result in a reduction of the Company’s interest expense associated with the shareholder loans.

Contact:

For queries, please contact:
aap Implantate AG; R. Di Girolamo; Chairman of the Management Board / CEO; Lorenzweg 5; D-12099 Berlin
Tel.: +49/30/750 19 – 170; Fax: +49/30/750 19 – 290; r.digirolamo@aap.de

 

*****

End of Inside Information


02-Nov-2026 CET/CEST The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Language: English
Company: aap Implantate AG
Lorenzweg 5
12099 Berlin
Germany
Phone: +49 (0) 30 75 019-0
Fax: +49 (0) 30 75 019-111
E-mail: info@aap.de
Internet: www.aap.de
ISIN: DE000A3H2101
WKN: A3H210
Listed: Regulated Market in Frankfurt (General Standard); Regulated Unofficial Market in Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate BSX
LEI Code: 39120001TRQTQ01LPP57
EQS News ID: 2426658

 
End of Announcement EQS News Service

2426658  02-Nov-2026 CET/CEST

Immunic to Participate in Investor Conferences in November

Issuer: Immunic AG

/ Key word(s): Conference

Immunic to Participate in Investor Conferences in November

02.11.2026 / 12:30 CET/CEST

The issuer is solely responsible for the content of this announcement.


Immunic to Participate in Investor Conferences in November

NEW YORK, November 2, 2026 – Immunic, Inc. (Nasdaq: IMUX), a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases, today announced participation in the following investor conferences in November: 

  • November 9-11: Guggenheim 3rd Annual Healthcare Innovation Conference. Erik Lundgren, Chief Executive Officer, and Jason Tardio, President and Chief Operating Officer, will participate in a fireside chat on Monday, November 9, 2026 at 1:00 pm ET at this conference in Boston. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations. 

Mr. Lundgren, Mr. Tardio, and Jessica Breu, Vice President Investor Relations and Communications at Immunic, will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Guggenheim representative or Jessica Breu at: jessica.breu@imux.com.

  • November 10-12: Stifel 2026 Healthcare Conference. Mr. Lundgren and Mr. Tardio will participate in a fireside chat on Wednesday, November 11, 2026 at 2:00 pm ET at this conference in New York. A webcast will be available on the “Events and Presentations” section of Immunic’s website at: https://ir.imux.com/events-and-presentations.

Mr. Lundgren, Mr. Tardio, and Mrs. Breu will also participate in one-on-one investor meetings at the conference. To schedule a meeting, please contact your Stifel representative or Jessica Breu at: jessica.breu@imux.com. 

  • November 17-18: Mr. Lundgren, Mr. Tardio, and Patrick Walsh, Chief Business Officer, will be hosting one-on-one meetings in London in connection with the Jefferies Global Healthcare Conference. To schedule a meeting, please contact Jessica Breu at: jessica.breu@imux.com.

Additionally, Immunic will host a Virtual Progressive Multiple Sclerosis R&D Day on Thursday, November 5, 2026 at 12:30 pm ET with management and two renowned experts in the treatment of multiple sclerosis (MS) and development of new therapies, Jiwon Oh, M.D., Ph.D., FRCPC, Division of Neurology, University of Toronto, and Maria Pia Sormani, Ph.D., University of Genoa, Italy. The group will discuss the key unmet needs in progressive MS and the persistent needs for innovative approaches to the development of therapies that target novel mechanisms associated with neurodegeneration and MS progression. Register here to attend. 

About Immunic, Inc.

Immunic, Inc. (Nasdaq: IMUX) is a late-stage biotechnology company pioneering the development of novel oral therapies for neurologic diseases. The company’s lead investigational asset, vidofludimus calcium (IMU-838), is currently being evaluated in Phase 3 clinical trials in relapsing multiple sclerosis, with top-line data expected to be available by the end of 2026. Initiation of an additional Phase 3 clinical trial in progressive multiple sclerosis is expected later in 2026. Vidofludimus calcium combines potential neuroprotective effects associated with nuclear receptor-related 1 (Nurr1) activation with anti-inflammatory and anti-viral effects associated with selective inhibition of the enzyme dihydroorotate dehydrogenase (DHODH). The company’s development pipeline also includes earlier-stage programs, including IMU-381 and IMU-856, aimed at building a broader therapeutics platform addressing neurodegenerative and autoimmune diseases. For further information, please visit: www.imux.com.

Cautionary Statement Regarding Forward-Looking Statements

This press release contains “forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided by the Private Securities Litigation Reform Act of 1995. All statements, other than statements of historical facts, included in this press release regarding strategy, future operations, future financial position, future revenue, projected expenses, sufficiency of cash and cash runway, expected timing, development and results of clinical trials, prospects, plans and objectives of management are forward-looking statements. Examples of such statements include, but are not limited to, statements relating to management’s and employee’s participation in investor conferences. Immunic may not actually achieve the plans, carry out the intentions or meet the expectations or projections disclosed in the forward-looking statements and you should not place undue reliance on these forward-looking statements. Such statements are based on management’s current expectations and involve substantial risks and uncertainties. Actual results and performance could differ materially from those projected in the forward-looking statements as a result of many factors, including, without limitation, increasing inflation, tariffs and macroeconomics trends, impacts of the Ukraine – Russia conflict and the conflict in the Middle East on planned and ongoing clinical trials, risks and uncertainties associated with the ability to project future cash utilization and reserves needed for contingent future liabilities and business operations, the availability of sufficient financial and other resources to meet business objectives and operational requirements, the fact that the results of earlier preclinical studies and clinical trials may not be predictive of future clinical trial results, any changes to the size of the target markets for the company’s products or product candidates, the protection and market exclusivity provided by Immunic’s intellectual property, risks related to the drug development and the regulatory approval process and the impact of competitive products and technological changes. A further list and descriptions of these risks, uncertainties and other factors can be found in the section captioned “Risk Factors,” in the company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2025, filed with the SEC on February 26, 2026, and in the company’s subsequent filings with the SEC. Copies of these filings are available online at www.sec.gov or ir.imux.com/sec-filings. Any forward-looking statement made in this release speaks only as of the date of this release. Immunic disclaims any intent or obligation to update these forward-looking statements to reflect events or circumstances that exist after the date on which they were made. Immunic expressly disclaims all liability in respect to actions taken or not taken based on any or all of the contents of this press release.

 

Contact Information

Immunic, Inc.
Jessica Breu
Vice President Investor Relations and Communications
+49 89 2080 477 09
jessica.breu@imux.com

US IR Contact
LifeSci Advisors
Joyce Allaire
immunic@lifesciadvisors.com

US Media Contact
Real Chemistry
media@imux.com

 


Dissemination of a Corporate News, transmitted by EQS News – a service of EQS Group.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases.


Atom Therapeutics to Present Phase 2b/3 Data Showing Superior Efficacy of Lingdolinurad (ABP-671), Compared to Febuxostat, for Patients with Chronic Gout and Hyperuricemia at ACR Convergence 2026

Atom Therapeutics to Present Phase 2b/3 Data Showing Superior Efficacy of Lingdolinurad (ABP-671), Compared to Febuxostat, for Patients with Chronic Gout and Hyperuricemia at ACR Convergence 2026




Atom Therapeutics to Present Phase 2b/3 Data Showing Superior Efficacy of Lingdolinurad (ABP-671), Compared to Febuxostat, for Patients with Chronic Gout and Hyperuricemia at ACR Convergence 2026

  • Lingdolinurad, a novel oral URAT1 inhibitor, achieved its primary endpoint in lowering serum uric acid (sUA) to < 6 mg/dL and a secondary endpoint in dissolution of tophi, an indicator of advanced gout, while also demonstrating a favorable safety and tolerability profile.
  • The China Phase 2b/3 trial results revealed lingdolinurad achieved statistically significant and clinically meaningful improvements for chronic gout patients compared to febuxostat, an oral xanthine oxidase inhibitor and commonly used medication that has been associated with severe adverse side effects.
  • In addition, data showed the proportion of patients achieving sUA < 6mg/dL after 8 weeks of treatment with 2 mg lingdolinurad twice daily was 91.9% compared to 51.6% for patients receiving 40 mg of febuxostat once daily.
  • Millions of people worldwide suffer from chronic gout and the numbers of patients are rising especially in the US, China and Europe. Current market therapies offer limited effectiveness.

HANGZHOU, China & NEWARK, Calif.–(BUSINESS WIRE)–Atom Therapeutics, a clinical stage biotechnology company developing new treatments for inflammatory and metabolic diseases, announced today Phase 2b/3 trial results showing lingdolinurad significantly outperformed febuxostat in treating chronic gout and hyperuricemia in Chinese patients will be presented at the American College of Rheumatology’s ACR Convergence 2026, November 6 – 11, in Orlando, FL. The data also confirm lingdolinurad achieved its primary and secondary endpoints in lowering serum uric acid (sUA) and dissolving tophi, an indicator of advanced chronic gout.


The abstract titled “A Multicenter, Randomized, Double-Blind, Placebo/Febuxostat-Controlled, Phase 2b/3 Study to Assess the Efficacy and Safety of ABP-671 in Participants With Gout and Hyperuricemia: Results from the 24-Week Extension Period of the Phase 2b Study” will be presented by Zhuoli Zhang, MD, of Peking University Hospital in Beijing, China, on Monday, November 9, 10:30 am to 12:30 pm US Eastern Time in Poster Session B (Metabolic & Crystal Arthopathies – Basic & Clinical Science).

William Dongfang Shi, PhD., Atom CEO, Chairman and Founder, said, “The results from this Phase 2b portion of our Phase 2b/3 trials not only reveal lingdolinurad’s superior efficacy over febuxostat, but also establish lingdolinurad’s favorable safety profile, optimum dose and remarkable effectiveness in lowering sUA levels and reduction or resolution of gout tophi. A Phase 3 trial in China is ongoing and data readout is expected in Q3/2027 followed by a China NDA submission in early 2028.”

Additionally, Atom’s three global Phase 3 studies will evaluate lingdolinurad as a monotherapy for chronic gout, as an add-on study in refractory gout, and as an add-on treatment for tophaceous gout.

Chronic gout, a growing global crisis, is caused by persistent hyperuricemia (sUA >7 mg/dL) that leads to the deposition of monosodium urate (MSU) crystals, triggering pain inflammation and tissue damage in joints, synovium, tendons, and kidneys. If hyperuricemia is inadequately controlled, accumulation of urate crystals can lead to tophaceous gout, the most severe form of chronic gout. Tophi can cause bone erosion, synovial thickening, joint deformity, and, in severe cases, loss of joint function and impaired renal function.

The China Phase 2b study results showed that after 8 weeks administering 2 mg lingdolinurad twice daily (with patients whose baseline mean sUA levels were 9.8 mg/dL), the proportions of those patients achieving sUA levels below 6 mg/dL, 5 mg/dL and 4 mg/dL exceeded 91%, 83%, and 63%, respectively, successfully obtaining the trial’s primary endpoint and showing significantly superior efficacy compared to febuxostat.

After 8 weeks, all patients received 2 mg lingdolinurad twice daily for 24 weeks to assess the impact of dissolving tophi as a secondary endpoint of the trial. Results demonstrated lingdolinurad exhibited outstanding tophi dissolution and reduction capability, with complete resolution of tophi in some subjects.

The data also demonstrated a favorable overall safety and tolerability profile for lingdolinurad throughout the study’s treatment period, consistent with the data from completed global studies.

About Atom Therapeutics

Atom Therapeutics is an innovative, clinical-stage biotechnology company focused on the discovery and development of novel therapies for metabolic, inflammatory, and cardiovascular diseases. The company’s lead product, lingdolinurad (ABP-671), is a highly potent and selective oral URAT1 inhibitor currently undergoing pivotal Phase 3 trials in China and globally for treatment of chronic gout, hyperuricemia, tophaceous gout, and refractory gout. Lingdolinurad is also in a Phase 2 study for CKD patients with hyperuricemia. Another compound ABP-745, targeting multiple pathways involved in inflammation, foam cell formation, myocardial remodeling and fibrosis, has demonstrated favorable pharmacokinetics and safety in Phase 1 trials and is in Phase 2 trials for treatment of acute gout flares and atherosclerotic cardiovascular disease. A pre-IND of Phase 2 for ABP-745 for treatment of heart failure with preserved ejection fraction was submitted to FDA in October 2026. ABP-745 is also planned for Phase 2 IND for recurrent pericarditis. For more information, visit www.atomthera.com or atomthera.us

Contacts

Media Contact:
Daniel Eramian
Opus Biotech Communications
http://opusbiotech.com/
425-306-8716

Business Development Contact:
Roy J. Wu, MBA
Sr. Vice President, Business Development
Atom Therapeutics Co., Ltd
Email: roy.wu@atombp.com

Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy

Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy




Sofinnova Partners Promotes Javier Nunez-Vicandi to Partner, Strengthening Its Digital Medicine Strategy

 Physician-investor and co-builder of Sofinnova’s AI platform Sofia joins the partnership, underscoring the firm’s growing interest in healthtech and techbio

PARIS–(BUSINESS WIRE)–Sofinnova Partners (“Sofinnova”), a leading European venture capital firm in life sciences, based in Paris, London, and Milan, today announced the promotion of Javier Nunez-Vicandi to Partner. He joins Edward Kliphuis and Simon Turner in the firm’s Digital Medicine strategy, which invests in startups working at the intersection of biology, data, and AI.


Since joining Sofinnova in 2022, Nunez-Vicandi has played a key role in the development of the firm’s Digital Medicine strategy and broader AI efforts. He helped shape key AI investment theses within the Digital Medicine Strategy and is an observer on the boards of Latent Labs, Bioptimus, Cure51, Deepc, and Kiro. Javier has also recently led an investment that remains in stealth. Within Sofinnova’s broader AI efforts, Javier co-led the project that created Sofia, Sofinnova’s proprietary AI platform, which supports investments and scientific analysis. As part of this effort, Javier helped lead the firm’s collaborations with AWS and NVIDIA.

The Sofinnova Digital Medicine strategy invests in healthtech, which applies technology to healthcare delivery, and techbio, which puts AI and other cutting-edge computational techniques to use in biological research and drug discovery.

“Javier combines clinical experience, scientific rigor and a deep understanding of technology,” said Antoine Papiernik, Chairman and Managing Partner at Sofinnova Partners. “Since joining the firm, he has become a trusted investor, a valued colleague and an important contributor to our Digital Medicine strategy. We are delighted to welcome him to the partnership.”

“My time seeing patients showed me just how critical getting treatments that work to the people that need them can be,” said Nunez-Vicandi. “It is a privilege to support world-class founders using AI to create a world of healthcare abundance at Sofinnova and I am excited to take on this new role.”

Before joining Sofinnova, Nunez-Vicandi was the first employee at Heal Capital, an early-stage healthtech venture capital fund. He helped grow the firm from launch to 12 investments. Previously, he was an analyst at M Ventures, where he focused on data-driven healthcare, biotechnology, and automation investments. He started his career practicing medicine at Oxford University Hospitals NHS Foundation Trust, including roles at the National Spinal Injuries Centre and Churchill Hospital. Nunez-Vicandi holds an MPhil (distinction) from the University of Cambridge and a Bachelor of Medicine, Bachelor of Surgery (MBBS) from Newcastle University.

About Sofinnova Partners

Sofinnova Partners is a leading European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London and Milan, the firm brings together a team of professionals from all over the world with strong scientific, medical and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life-sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners has over 50 years of experience backing over 500 companies and creating market leaders around the globe. Today, Sofinnova Partners manages over €4 billion in assets. For more information, please visit: sofinnovapartners.com.

Contacts

Sofinnova Partners
Bommy Lee
Head of Communications

blee@sofinnovapartners.com
+33 (0) 6 47 71 38 11

Media inquiries:

United Kingdom
Optimum Strategic Communications

Eleanor Cooper

sofinnova@optimumcomms.com
+44 (0) 20 4604 4016

France
Strategies&Image (S&I)

Anne Rein

anne.rein@strategiesimage.com
+33 (0) 6 03 35 92 05

Italy
Havas PR Milan

Pierluigi Cavarai

pierluigi.cavarai-ext@havaspr.com
+39 (0) 392 77 999 33

Iksuda to Present Clinical Data for IKS014 in HER2+ Solid Tumours at SABCS

Iksuda to Present Clinical Data for IKS014 in HER2+ Solid Tumours at SABCS




Iksuda to Present Clinical Data for IKS014 in HER2+ Solid Tumours at SABCS

Excellent therapeutic profile with manageable and differentiated safety profile and promising anti-tumour activity in patients with a range of advanced HER-2-expressing solid tumours

Positive activity in a subset of HER2+ breast cancer patients previously treated with Enhertu (T-DXd)

NEWCASTLE, England–(BUSINESS WIRE)–Iksuda Therapeutics (Iksuda), the developer of class leading, antibody drug conjugates (ADCs), today announces the presentation of preliminary data from its Phase 1 study for its HER2-directed ADC, IKS014, which is being assessed in patients with advanced or metastatic HER2+, HER2-low and HER2-mutated solid tumours, at the San Antonio Breast Cancer Symposium (SABCS), December 8-11, 2026, San Antonio, Texas.

Additionally, the presentation includes a pooled analysis from dose escalation- and dose-expansion phases of the trial for a sub-set of HER2+ breast cancer patients who have previously received trastuzumab-deruxtecan (Enhertu/ ‘T-DXd’). This is an important patient population given the clinical challenges of ADC sequencing, and with T-DXd now approved as a front-line treatment in these patients.

As of April 2026, 105 patients with a variety of tumours were enrolled across Part I dose escalation and Part II dose expansion cohorts. Overall, 71 patients were enrolled in Part 1 dose escalation (DE) /enrichment cohorts and treated at doses from 40 – 120 mg/m2 once every three weeks. A maximum tolerated dose (MTD) was not identified but a dose of 105 mg/m2 was selected for further evaluation in expansion cohorts based on its promising efficacy across tumour types and a good, differentiated safety profile. 34 patients have been enrolled into Part II to date across 5 expansion cohorts (ECs), one of which (IIA) includes patients with HER2+ BC previously treated with T-DXd.

In the 105 patients, IKS014 has been shown to be well tolerated with a differentiated and manageable safety profile. Only 16 patients (15.2%) experienced Grade 3 treatment-related adverse events (TRAEs), of which seven patients (6.7%) experienced hypokalaemia as the most common event. Compared with other HER2-directed ADCs, there was a notable absence in the frequency of high-grade, pneumonitis/ILD, neutropenia, anaemia, fatigue, AST elevation and GI toxicities. The most common TRAEs were low-grade (G1 or G2) hypokalaemia (36%), dry eye (34%), keratitis (34%) and dry mouth (28%). No Grade 5 events or treatment-related serious adverse events were noted.

Pooled efficacy analysis consisted of 10 response-evaluable patients with advanced or metastatic HER2+ breast cancer previously treated with T-DXd, including four patients treated at ≥90 mg/m2 in DE cohorts and six patients treated in the EC. Patients were heavily pre-treated, with a median number of regimens of 6 and a range of 2-12. The objective response rate was 50% (n=5/10), which consisted of confirmed and unconfirmed partial responses. Of particular note, PRs were observed in patients who had a best response of PD to prior T-DXd, and sustained responses were also observed, including in one patient with a response of over 18 months. Alongside the good safety profile, these efficacy results are highly encouraging.

As an evolving dataset, the final SABCS presentation will contain updated data.

The IIA EC will recruit 25 patients in total. Expansion Cohort IIA will continue to recruit patients with HER2+ BC previously treated with T-DXd, whilst patients with advanced or metastatic HER2-low BC, HER2+ gastric/ GEJ and oesophageal cancers, and HER2-mutated lung cancer will continue to be recruited to the additional expansion cohorts.

Dr. Dave Simpson, Chief Executive Officer, Iksuda Therapeutics, commented: “The data from our Phase 1 study of IKS014 is extremely exciting, with promising antitumor activity seen in patients with advanced HER2+ solid tumours across multiple histologies, alongside a differentiated and manageable safety profile. We are strongly encouraged by the efficacy in patients who have previously received T-DXd, a patient population with high unmet need, and we look forward to continuing with dose expansion and the enrolment of these patients.”

Dr. James O’Leary, Chief Medical Officer at Iksuda Therapeutics, added: “These data demonstrate the potential of IKS014 to address the high unmet need across various HER2-positive cancers, including for patients who have not responded to previous lines of treatment.”

The Phase 1 study (NCT05872295) is an open-label, multicentre trial of IKS014 in patients with HER2-expressing advanced solid tumours refractory to or progressing after standard therapies. Part I (Dose Escalation) will establish a recommended Expansion Dose and Part 2 (Dose Expansion) will further evaluate the safety, pharmacokinetics, pharmacodynamics and efficacy of IKS014 in five cohorts, including one for patients with HER2+ breast cancer who have previously been treated with T-DXd. IKS014 has been evaluated by a separate sponsor in trials conducted exclusively in China, including an ongoing Phase 3 trial in breast cancer.

Presentation details

Abstract number: 602

Presentation Number: PS3-1

Title: A Phase 1 study of IKS014 (caxmotabart entudotin) in patients with HER2+ solid tumours, and preliminary activity in breast cancer patients previously treated with trastuzumab deruxtecan

Presentation Date/Time: Wednesday, December 9, 2026, 7:00 AM – 8:30 AM CST

Location: 301 ABC

About IKS014

IKS014 is a potential best-in-class antibody drug conjugate, benefiting from tumour selective activation and release of the cytotoxic agent monomethyl auristatin F (MMAF). In preclinical trials, it displayed impressive activity in high- and low-HER2 expressing tumours with a favourable Therapeutic Index compared with other HER2-directed drugs. Iksuda gained exclusive world-wide rights (excluding Greater China and South Korea) to IKS014 from LigaChem Biosciences (https://iksuda.com/2022/01/iksuda-deepens-clinical-pipeline/).

About Iksuda Therapeutics: www.iksuda.com

Iksuda Therapeutics is a clinical stage, UK-based biotechnology company focussed on the development of class leading ADCs targeting difficult-to-treat haematological and solid tumours. Iksuda’s pipeline of ADCs is centred on a portfolio of prodrug ADCs which utilise tumour-selective release and activation of payloads, incorporating proprietary and in-licensed (from LigaChem Biosciences) prodrug and linker technologies in combination with stable conjugation chemistries including its proprietary PermaLink® platform. The early pipeline incorporates Iksuda’s proprietary, first-in-class protein alkylating payload class, ProAlk™. The Company’s design concepts for ADCs are now clinically validated to significantly improve the therapeutic index of this important modality and improve the outcomes for patients living with cancer.

Contacts

For further information please contact:

Iksuda Therapeutics
Dave Simpson, Chief Executive Officer

Tel: +44 (0) 191 6031680

info@iksuda.com

FTI Consulting (Financial Media and IR)
Simon Conway / Natalie Garland-Collins / Amy Byrne

Tel: +44 (0) 020 3727 1000

Iksuda@fticonsulting.com

PolyPeptide Group: Provisional end result of the public tender offer of Samsung Biologics Co., Ltd.

PolyPeptide Group / Key word(s): Tender Offer

PolyPeptide Group: Provisional end result of the public tender offer of Samsung Biologics Co., Ltd.

02-Nov-2026 / 07:05 CET/CEST

Release of an ad hoc announcement pursuant to Art. 53 LR

The issuer is solely responsible for the content of this announcement.


Media Release – ad hoc announcement pursuant to Art. 53 LR

Provisional end result of the public tender offer of Samsung Biologics Co., Ltd.

Baar, Switzerland, 2 November 2026 – Samsung Biologics Co., Ltd. (“Samsung Biologics”), through its direct subsidiary Samsung Peptide AG (“Samsung Peptide”), today published the provisional end result of its public tender offer (the “Offer”) for all publicly held registered shares of PolyPeptide Group AG (“PolyPeptide”) (SIX: PPGN).

The additional acceptance period of the Offer ended on 30 October 2026, at 4:00 p.m. Swiss time. According to the provisional end result as published by Samsung Peptide,

  • the participation of Samsung Peptide and the persons acting in concert with Samsung Peptide amounts to 32,458,892 PolyPeptide shares in aggregate, corresponding to 97.99% of the issued share capital and voting rights of PolyPeptide (participation rate); and
  • 32,350,302 PolyPeptide shares were tendered into the Offer until the end of the additional acceptance period of the Offer, corresponding to 97.66% of the issued share capital and voting rights of PolyPeptide and 97.98% of all PolyPeptide shares to which the Offer relates (success rate).

The end result that has been published today by Samsung Peptide is provisional and is available at https://samsungbiologics.com/offer. The definitive end result is expected to be published on 5 November 2026.

According to the provisional end result as published by Samsung Peptide, the Offer remains subject to certain remaining Offer conditions, including the receipt of regulatory approvals in certain jurisdictions.

In its provisional end result, Samsung postponed the settlement of the Offer in accordance with section B.7.3 (Period for which the Offer Conditions are in Force and Effect and Deferral) of the Offer Prospectus and confirmed that based on the current understanding of the regulatory approval procedures in various countries (see the Offer condition pursuant to section B.7.1(b) (Merger and FDI Clearances) of the Offer Prospectus), the transaction is currently expected to be completed towards the end of 2026 or in Q1 2027.

According to the provisional end result as published by Samsung Peptide, Samsung Peptide intends to pursue a squeeze-out of any remaining public shareholders and to apply to SIX Exchange Regulation for the delisting of the PolyPeptide shares following the settlement of the Offer.

 

Contact

PolyPeptide Group AG
Strategic Marketing and Corporate Communications
Laura Rosso
mediateam@polypeptide.com
T: +41 43 502 0580 

PolyPeptide Group AG
Finance / Investor Relations
Tim Brandl
investorrelations@polypeptide.com 
T: +41 43 502 0580
 

About PolyPeptide

PolyPeptide Group AG and its consolidated subsidiaries (“PolyPeptide”) is a specialized Contract Development & Manufacturing Organization (CDMO) for peptide-based active pharmaceutical ingredients. By supporting its customers mainly in pharma and biotech, it contributes to the health of millions of patients across the world. PolyPeptide serves a fast-growing market, offering products and services from pre-pre-clinical to commercial stages. Its broad portfolio reflects the opportunities in drug therapies across areas and with significant exposure to metabolic diseases, including GLP-1. Dating back to 1952, PolyPeptide today runs a global network of six GMP-certified facilities in Europe, the U.S. and India. PolyPeptide’s shares (SIX: PPGN) are listed on SIX Swiss Exchange. For more information, please visit polypeptide.com.

@PolyPeptide — follow us on LinkedIn

About Samsung Peptide and Samsung Biologics

Samsung Peptide is a direct subsidiary of Samsung Biologics. Samsung Biologics and PolyPeptide have concluded a transaction agreement on 17 July 2026 regarding the Offer. Samsung Peptide is acting as the formal offeror of the Offer. Samsung Biologics (KRX: 207940.KS) is a leading Contract Development & Manufacturing Organization (CDMO), offering end-to-end integrated services that range from late discovery to commercial manufacturing. With a combined biomanufacturing capacity of 785,000 liters across Bio Campus I and II in Korea, and 60,000 from the manufacturing facility in Rockville, Maryland, U.S., Samsung Biologics holds total global manufacturing capacity of 845,000 liters. Samsung Biologics has also secured land for Bio Campus III, laying the groundwork for future capacity expansion to support next-generation therapies and emerging modalities. Samsung Biologics leverages cutting-edge technologies and expertise to advance diverse modalities, including multispecific antibodies, fusion proteins, antibody-drug conjugates, and mRNA therapeutics. By implementing the ExellenS™ framework across its manufacturing network with standardized designs, unified processes, and advanced digitalization, Samsung Biologics ensures plant equivalency and speed for manufacturing continuity. Samsung Biologics’ global manufacturing and commercial network spans Korea, the U.S., Europe, and Japan. Samsung Biologics continues to invest in new capabilities to maximize operational and quality excellence, ensuring flexibility and agility for clients. Samsung Biologics is committed to the on-time, in-full delivery of safe, high-quality biomedicines, as well as to making sustainable business decisions for the betterment of society and global health. For more information, please visit https://samsungbiologics.com.

Legal Notice and Disclaimer

No Offer / Offer Restrictions

The information in this media release is for informational purposes only. It does not constitute, or form part of, any offer or invitation to purchase, sell, exchange or issue, or any solicitation of an offer to sell, purchase, exchange or subscribe to, any registered shares or other securities of PolyPeptide or any other person, nor shall it form the basis of, or be relied upon in connection with, any contract in relation thereto. This media release is not part of Samsung Peptide’s publication of the provisional end result of the Offer or any other publication, communication or other documentation of Samsung Peptide or Samsung Biologics relating to the Offer, including without limitation the Offer Prospectus (the “Offer Documentation”). Terms and conditions of the Offer have been published by Samsung Peptide and Samsung Biologics in the Offer Documentation. Shareholders of PolyPeptide are urged to read the Offer Documentation, which is available at https://samsungbiologics.com/offer.

This announcement is not for publication, release or distribution in any country or jurisdiction in which it would be considered unlawful or otherwise violate any applicable laws or regulations, or which would require Samsung Peptide or Samsung Biologics to change or amend the terms or conditions of the Offer in any way, to make an additional filing with any governmental, regulatory or other authority or take additional action in relation to the Offer. Full Offer restrictions can be found in Samsung Peptide’s Offer Prospectus at https://samsungbiologics.com/offer.

Forward-looking Information and Statements

This media release has been prepared by PolyPeptide and includes forward-looking information and statements concerning the outlook for the Group’s business. These statements are based on current expectations, estimates and projections about the factors that may affect the Group’s future performance. These expectations, estimates and projections are generally identifiable by statements containing words such as ‘expects’, ‘believes’, ‘estimates’, ‘targets’, ‘plans’, ‘projects’, ‘outlook’ or similar expressions. There are numerous risks, uncertainties and other factors, many of which are beyond PolyPeptide’s control, that could cause the group’s actual results to differ materially from the forward-looking information and statements made in this media release and that could affect the group’s ability to achieve its stated targets. Although PolyPeptide believes that its expectations reflected in any such forward-looking statement are based upon reasonable assumptions, it can give no assurance that those expectations will be achieved.

Except as otherwise required by law, PolyPeptide disclaims any intention or obligation to update any forward-looking statements as a result of developments.

 

Additional features:

File: 20261102_PolyPeptide_Media_Release_Tender_Offer


End of Inside Information


Language: English
Company: PolyPeptide Group
Neuhofstrasse 24
6340 Baar
Switzerland
Phone: +41435020580
E-mail: mediateam@polypeptide.com
Internet: www.polypeptide.com
ISIN: CH1110760852
Valor: 111076085
Listed: SIX Swiss Exchange
EQS News ID: 2426080

 
End of Announcement EQS News Service

2426080  02-Nov-2026 CET/CEST

Medartis reports accelerating US momentum on faster adoption of TOUCH® thumb joint prosthesis

In the United States, the rollout of TOUCH, a CMC 1 prosthesis for the treatment of thumb base osteoarthritis (rhizarthrosis), is gaining momentum. Adoption is progressing faster than initially anticipated, with more than 2,000 procedures performed by October 2026. For the full year, Medartis now expects approximately 3,000 TOUCH procedures in the US. Outside the US, both the arthroplasty and the fixation businesses continue to perform robustly, led by EMEA, Medartis’ largest region.

If the current demand pattern continues, Medartis is confident to overachieve its organic core sales growth guidance of 17% to 19% (CER). In this scenario, operating leverage from higher sales will bring the core EBITDA margin to the upper end of the guidance (“high-teens range”).

Matthias Schupp, CEO of Medartis, commented: “Momentum in the US has increased since the half-year results. The clinical track record of TOUCH in Europe over more than a decade, close collaboration with leading US surgeons and the benefits of thumb arthroplasty over trapeziectomy have quickly built surgeon confidence, leading to faster adoption than previously anticipated. With increased visibility for the remainder of the year, we are well positioned to overachieve our financial guidance in 2026.”

Medartis will publish its full-year 2026 results on 2 March 2027. In the meantime, management will present at several investor conferences, including the Jefferies Healthcare Conference in London, the ZKB Swiss Equity Conference in Zurich and the Octavian Equity Seminar in Davos.

 

Picture download: https://photos.app.goo.gl/4eKtXhUeqR1mNj3W7